Overview
Allogeneic stem cell transplantation with a focus on the use of umbilical cord blood grafts; Allogenic stem cell transplantation for Sickle Cell Disease; Prevention of acute and chronic graft versus host disease; Improving immune recovery following alternative donor stem cell transplantation using donor graft manipulation.
Current Appointments & Affiliations
Professor of Medicine
·
2016 - Present
Medicine, Hematologic Malignancies and Cellular Therapy,
Medicine
Member of the Duke Cancer Institute
·
2003 - Present
Duke Cancer Institute,
Institutes and Centers
Affiliate of the Duke Regeneration Center
·
2021 - Present
Duke Regeneration Center,
Basic Science Departments
Recent Publications
Exploring facilitators and barriers to daily chlorhexidine gluconate bathing in adult patients undergoing hematopoietic stem cell transplantation.
Journal Article Support Care Cancer · November 28, 2024 UNLABELLED: Hematopoietic cell transplantation (HCT) is a promising treatment for hematologic malignancies, but intensive conditioning leads to immunosuppression and susceptibility to healthcare-associated infections (HAI). Despite standard prevention meas ... Full text Link to item CiteLong-term survival after unrelated donor marrow transplantation for aplastic anaemia after optimized conditioning regimen: a retrospective multicentre cohort study.
Journal Article EClinicalMedicine · October 2024 BACKGROUND: Almost all acquired severe aplastic anaemia is immune mediated and characterised by hypocellular bone marrow and ≥2 affected haematopoietic lineages. The optimal preparartive regimen for unrelated donor transplantation remains to be established ... Full text Link to item CiteCorrigendum to 'Multicenter Long-Term Follow-Up of Allogeneic Hematopoietic Cell Transplantation with Omidubicel: A Pooled Analysis of Five Prospective Clinical Trials'.
Journal Article Transplant Cell Ther · August 2024 Full text Link to item CiteRecent Grants
Blood and Marrow Transplant Clinical Trials Network
Clinical TrialPrincipal Investigator · Awarded by National Institutes of Health · 2001 - 2031A Phase II Trial of Non-Myeloablative Conditioning and Transplantation of Haploidentical Related, Partially HLA-Mismatched, or Matched Unrelated Bone Marrow for Newly Diagnosed Patients with Severe Aplastic Anemia
Clinical TrialPrincipal Investigator · Awarded by National Marrow Donor Program · 2025 - 2030A randomized, open-label study evaluating the efficacy and safety of cemacabtagene ansegedleucel in participants with minimal residual disease after response to first line therapy for large B-cell lymphoma (ALPHA3)
Clinical TrialPrincipal Investigator · Awarded by Allogene Therapeutics, Inc. · 2024 - 2029View All Grants
Education, Training & Certifications
Rush University ·
1992
M.D.